Where does Optimus Drugs Private Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Optimus Drugs Private Limited ranks #32,757 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Optimus Drugs Private Limited hold?

Optimus Drugs Private Limited holds 8 US utility patents granted between 2017 and 2023, spanning 4 technology areas.

What is Optimus Drugs Private Limited's Innovation Score?

Optimus Drugs Private Limited has an Innovation Score of 24.6 out of 100 (15th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Optimus Drugs Private Limited focus on?

Optimus Drugs Private Limited's top technology area is C07D (Heterocyclic Compounds) with 5 patents. Grants appear in 4 CPC subclasses total.

Is Optimus Drugs Private Limited's patent grant rate increasing or decreasing?

Optimus Drugs Private Limited's recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Optimus Drugs Private Limited's patents?

Optimus Drugs Private Limited's patents average 5.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Optimus Drugs Private Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Optimus Drugs Private Limited

USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Optimus ranks #32,757 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.

#32,757
of 49,997 US assignees by volume: 15th percentile
by Innovation Score (24.6/100): 5.4
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32757 · Foreign Corporation #32,757 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,757/49,997
PHOTO-FINISH Optech Ventures
CPC-NARROW C07D · 4 areas
INNOV-THIN 24.6/100
CLAIMS-SPARSE 5.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Optech Ventures, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Optimus Drugs Private · this assignee

25
3D Lighting… · lowest

7

What this shows Optimus's Innovation Score is 24.6/100 (15th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Optimus's grants concentrate

Optimus Drugs Private Limited is a focused PatentsView assignee: 4 CPC subclasses with 62.5% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2022. By volume, Optimus sits between OptMed, Inc. and Orbray Co., Ltd..

Optimus's three-year grant acceleration

Optimus Drugs Private Limited shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Optmed

8
Optech Ventures

8
Opteon

8
Optimal Ventures

8
Optivolt Labs

8
Optofluidics

8
Orbital Composites

8
Orbray

8
Optimus Drugs Pri… ◀

8

What this shows Optimus holds 8 patents at rank #32,755, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Optimus

By rank, the assignees closest to #32,755 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Optimus's primary technology class.

Optimus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

25 15th percentile higher than 15% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Optimus Drugs Private Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	2	25.0%
2018	2	25.0%
2019	2	25.0%
2022	1	12.5%
2023	1	12.5%

Which technologies does Optimus Drugs Private Limited patent most?

C07D - Heterocyclic Compounds 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C07C - Acyclic OR Carbocyclic Compounds 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#32,757

of 49,997 tracked assignees

Innovation Score

24.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Optimus Drugs Private Limited's patent record in context - here's where to go next.

Optimus Drugs Private Limited's lead technology class is C07D (Heterocyclic Compounds), 62.5% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #32,757 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Optimus Drugs Private Limited against OptMed, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 24.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.